A Phase 1 interventional study of AG10 oral tablet and Placebo Oral Tablet in Amyloid Cardiomyopathy, Transthyretin-Related, sponsored by Eidos Therapeutics, a BridgeBio company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Eidos Therapeutics, a BridgeBio company · Phase 1, Interventional, and Treatment
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
Up to 48 healthy volunteers will be given a single dose of AG10 or placebo and be monitored for safety and tolerability over a 5-day period. Up to 48 healthy volunteers will be given multiple doses of AG10 or placebo and be monitored for safety and tolerability over a 15-day period.
Exclusion Criteria:
AG10 oral tablet, administered by mouth, once
Drug: AG10 oral tablet
Placebo Oral Tablet, administered by mouth, once
Drug: Placebo Oral Tablet
Active single ascending dose
Also known as: Eidos Therapeutics AG10
Placebo single dose
Also known as: Matching placebo
Safety & tolerability: individual and summary blood pressures, heart rate, ECG and lab data presented in tabular form with descriptive statistics. Adverse events will be tabulated and summarized by Part A (SAD) vs. B (MAD), and treatment.
To evaluate the safety and tolerability of single and multiple doses of AG10 administered to healthy adult subjects
Time frame: 30 days
Pharmacokinetic Assessments: T1/2
Plasma half-life (t1/2)
Time frame: 30 days
Pharmacokinetic Assessments: Tmax
Time to maximum concentration (Tmax)
Time frame: 30 days
Pharmacokinetic Assessments: Cmax
Maximum concentration (Cmax)
Time frame: 30 days
Pharmacokinetic Assessments: Cmin
Cmin
Time frame: 30 days
Pharmacokinetic Assessments: AUC
Area under the plasma concentration-time curve (AUC)
Time frame: 30 days
Pharmacokinetic Assessments: Clearance
Apparent clearance (CL/F)
Time frame: 30 days
Pharmacokinetic Assessments: volume of distribution
Apparent volume of distribution (Vss/F)
Time frame: 30 days
Pharmacodynamic Assessments: Assessments of TTR stabilization will be listed and summarized by part, treatment, and time point using appropriate descriptive statistics.
AG10 binding to and/or stabilization of TTR will be evaluated by established ex vivo assays, including Fluorescent Polarization Exclusion Assay (FPE) and Immunoblotting (Western Blot) and quantitation of prealbumin (TTR).
Time frame: 30 days
Pharmacodynamic Assessments: Western blot
AG10 binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: Immunoblotting (Western Blot)
Time frame: 30 days
Pharmacodynamic Assessments: prealbumin
AG10 binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: quantitation of prealbumin (TTR).
Time frame: 30 days
Food effect: AUC
To evaluate the effect of food on the PK of AG10. The log transformed values of total AUC will be analyzed using a linear mixed effect model with formulation, period, sequence, and carryover as fixed effects and subject as a random effect.
Time frame: 30 days
Food effect: Cmax
To evaluate the effect of food on the PK of AG10. The log transformed values of Cmax will be analyzed using a linear mixed effect model with formulation, period, sequence, and carryover as fixed effects and subject as a random effect.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eidos Therapeutics, a BridgeBio company